Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Endologix LLC

Endologix Announces that Scott Huennekens Joins Board of Directors
From Endologix LLC
Via Business Wire
Endologix Announces 1000 patients treated with the DETOUR™ System
From Endologix LLC
Via Business Wire
Endologix Appoints Andrew Davis as Chief Commercial Officer
From Endologix LLC
Via Business Wire
Endologix Announces Leadership Transition
From Endologix LLC
Via Business Wire
Endologix Announces 36-Month Results of DETOUR2 Study at 2024 VIVA Late-Breaking Clinical Trial Session
From Endologix LLC
Via Business Wire
Endologix to Present at 22nd Annual Global Morgan Stanley Conference
From Endologix LLC
Via Business Wire
Endologix Appoints Graham Phillips as Chief Operating Officer
From Endologix LLC
Via Business Wire
One-Year Results of the DETOUR2 Trial published in the Journal of Vascular Surgery (JVS)
From Endologix LLC
Via Business Wire
Endologix to Present at Upcoming LSI US ’24 Emerging Medtech Summit
From Endologix LLC
Via Business Wire
Endologix Appoints Mike Mathias as Chief Commercial Officer
From Endologix LLC
Via Business Wire
Endologix Initiates Percutaneous Transmural Arterial Bypass (PTAB)1 Post-Market Study
From Endologix LLC
Via Business Wire
Endologix Announces that Art Taylor Joins Board of Directors
From Endologix LLC
Via Business Wire
Endologix Announces that Scott Ward Joins Board of Directors
From Endologix LLC
Via Business Wire
Endologix announces the U. S. Centers for Medicare & Medicaid Services granted a Transitional Pass-Through (TPT) Payment for the DETOUR™ System
From Endologix LLC
Via Business Wire
Endologix to Present in Two Upcoming Healthcare Conferences
From Endologix LLC
Via Business Wire
Endologix Announces Results of Pooled Analysis of DETOUR1 and DETOUR2 Studies at 2023 VIVA Late-Breaking Clinical Trial Session
From Endologix LLC
Via Business Wire
Endologix's DETOUR™ System Earns Spot in Local and National Award Forums; Nominated for Prix Galien USA's Best Medical Technology
From Endologix LLC
Via Business Wire
Endologix announces the U. S. Centers for Medicare & Medicaid Services granted a New Technology Add-on Payment for the DETOUR System
From Endologix LLC
Via Business Wire
Endologix Announces that Lucas Buchanan Joins Board of Directors
From Endologix LLC
Via Business Wire
Endologix Announces First Patients Treated with the DETOUR™ System, Advancing Treatment for Complex Peripheral Artery Disease
From Endologix LLC
Via Business Wire
Endologix Announces 24-Month Results of DETOUR-2 Study at 2023 Vascular Annual Meeting
From Endologix LLC
Via Business Wire
Endologix Receives FDA Approval of the DETOUR™ System to Treat Long Complex Superficial Femoropopliteal Lesions in Patients with PAD
From Endologix LLC
Via Business Wire
Endologix Announces 150th Patient Enrolled in JAGUAR Randomized Controlled Trial
From Endologix LLC
Via Business Wire
Endologix Wins “Medical Device Engineering Breakthrough” Award in 7th Annual MedTech Breakthrough Awards Program
From Endologix LLC
Via Business Wire
Five-Year Results of the LEOPARD Trial published in the Journal of Vascular Surgery (JVS)
From Endologix LLC
Via Business Wire
Endologix Receives FDA Approval of PMA Supplement for AFX2 System
From Endologix LLC
Via Business Wire
Endologix Announces 12-Month Results of DETOUR-2 Trial at 2022 VIVA Late-Breaking Clinical Trial Session
From Endologix LLC
Via Business Wire
Endologix Reports Five-Year Data of the LEOPARD Trial at 2022 Vascular InterVentional Advances (VIVA) Conference
From Endologix LLC
Via Business Wire
ELEVATE IDE Study highlights the Safety and Effectiveness of the ALTO® Abdominal Stent Graft System in One-year Results; Data to Be Presented at 2022 VEITHsymposium
From Endologix LLC
Via Business Wire
Endologix Submits Premarket Approval (PMA) Application to FDA for the DETOURTM System.
From Endologix LLC
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.